Taylor Morrison Home (TMHC) At $24.28 Forms Top; 5 Bullish Analysts Covering Conatus Pharmaceuticals Inc. (CNAT)

Among 5 analysts covering Conatus Pharma (NASDAQ:CNAT), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Conatus Pharma had 10 analyst reports since September 22, 2015 according to SRatingsIntel. The rating was maintained by Stifel Nicolaus with “Buy” on Wednesday, November 9. Stifel Nicolaus maintained Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) on Tuesday, December 20 with “Buy” rating. The firm earned “Buy” rating on Friday, July 1 by Roth Capital. The rating was initiated by H.C. Wainwright on Tuesday, September 22 with “Buy”. As per Thursday, August 3, the company rating was maintained by Stifel Nicolaus. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, November 5 report. The stock of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) earned “Buy” rating by H.C. Wainwright on Thursday, June 29. The stock of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) earned “Buy” rating by H.C. Wainwright on Tuesday, December 20. See Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) latest ratings:

06/10/2017 Broker: Seaport Global Rating: Buy New Target: $16 Initiates Coverage On
03/08/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $10.0000 Maintain
29/06/2017 Broker: H.C. Wainwright Rating: Buy New Target: $18.0000 Maintain

Taylor Morrison Home Corporation (TMHC) formed multiple top with $26.47 target or 9.00% above today’s $24.28 share price. Taylor Morrison Home Corporation (TMHC) has $2.66 billion valuation. The stock decreased 0.37% or $0.09 during the last trading session, reaching $24.28. About 461,698 shares traded. Taylor Morrison Home Corporation (NYSE:TMHC) has risen 72.45% since December 22, 2016 and is uptrending. It has outperformed by 55.75% the S&P500.

Investors sentiment decreased to 1.18 in Q3 2017. Its down 2.01, from 3.19 in 2017Q2. It worsened, as 35 investors sold Taylor Morrison Home Corporation shares while 42 reduced holdings. 21 funds opened positions while 70 raised stakes. 69.48 million shares or 50.77% less from 141.13 million shares in 2017Q2 were reported. 221,888 were reported by Nationwide Fund. Acadian Asset Ltd holds 219,626 shares. 33,869 were accumulated by Breton Hill Ltd. Piermont Mgmt has 121,960 shares for 0.89% of their portfolio. Chicago Equity Partners Lc owns 15,470 shares. Ameritas Partners Inc reported 5,369 shares. Ajo L P owns 2.16 million shares for 0.21% of their portfolio. James Investment Rech Incorporated holds 73,600 shares. Legal & General Grp Public Ltd Liability Corp reported 0% of its portfolio in Taylor Morrison Home Corporation (NYSE:TMHC). Ny State Common Retirement Fund stated it has 261,456 shares or 0.01% of all its holdings. Great West Life Assurance Can has invested 0% in Taylor Morrison Home Corporation (NYSE:TMHC). Check Capital Management Inc Ca holds 0.02% or 26,000 shares in its portfolio. Moreover, Sg Americas Securities Lc has 0.01% invested in Taylor Morrison Home Corporation (NYSE:TMHC). Mutual Of America Cap Mngmt Limited Liability Co invested 0.01% in Taylor Morrison Home Corporation (NYSE:TMHC). Nordea Investment Management has 0% invested in Taylor Morrison Home Corporation (NYSE:TMHC).

Among 11 analysts covering Taylor Morrison Home Corporation (NYSE:TMHC), 3 have Buy rating, 0 Sell and 8 Hold. Therefore 27% are positive. Taylor Morrison Home Corporation has $27 highest and $14 lowest target. $20.06’s average target is -17.38% below currents $24.28 stock price. Taylor Morrison Home Corporation had 26 analyst reports since August 6, 2015 according to SRatingsIntel. Deutsche Bank maintained Taylor Morrison Home Corporation (NYSE:TMHC) rating on Tuesday, February 9. Deutsche Bank has “Buy” rating and $20 target. The firm has “Outperform” rating by Credit Suisse given on Tuesday, March 8. On Thursday, August 6 the stock rating was upgraded by Sterne Agee CRT to “Buy”. Gabelli downgraded the shares of TMHC in report on Thursday, December 8 to “Hold” rating. As per Thursday, August 4, the company rating was maintained by Citigroup. FBR Capital maintained the shares of TMHC in report on Thursday, November 5 with “Outperform” rating. The rating was initiated by Barclays Capital with “Equal Weight” on Friday, January 6. The stock of Taylor Morrison Home Corporation (NYSE:TMHC) has “Buy” rating given on Monday, September 21 by Deutsche Bank. The firm has “Buy” rating given on Tuesday, August 9 by Deutsche Bank. The stock has “Neutral” rating by Wedbush on Tuesday, September 20.

Since October 4, 2017, it had 0 buys, and 1 insider sale for $456,568 activity. Cone C. David sold $456,568 worth of stock.

Analysts await Taylor Morrison Home Corporation (NYSE:TMHC) to report earnings on January, 29. They expect $0.66 earnings per share, up 1.54% or $0.01 from last year’s $0.65 per share. TMHC’s profit will be $72.31 million for 9.20 P/E if the $0.66 EPS becomes a reality. After $0.45 actual earnings per share reported by Taylor Morrison Home Corporation for the previous quarter, Wall Street now forecasts 46.67% EPS growth.

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. The company has market cap of $149.73 million. The Company’s product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. It currently has negative earnings.

Investors sentiment decreased to 1.83 in 2017 Q3. Its down 1.94, from 3.77 in 2017Q2. It worsened, as 9 investors sold Conatus Pharmaceuticals Inc. shares while 14 reduced holdings. 21 funds opened positions while 21 raised stakes. 10.89 million shares or 43.42% less from 19.24 million shares in 2017Q2 were reported. Strs Ohio reported 26,700 shares. Bnp Paribas Arbitrage reported 2,496 shares. Wells Fargo And Mn holds 19,188 shares. Denver Invest Limited Company invested in 0% or 10,715 shares. Northern Trust has invested 0% of its portfolio in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Acadian Asset Management Lc invested in 0.03% or 1.09M shares. State Street holds 0% or 372,111 shares. Bridgeway Cap Management stated it has 0.01% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Alliancebernstein Limited Partnership owns 10,200 shares. Sterling Capital Ltd, a North Carolina-based fund reported 129,011 shares. Invesco has invested 0% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Jasper Ridge Partners Lp holds 15,677 shares. Credit Suisse Ag accumulated 17,540 shares or 0% of the stock. D E Shaw accumulated 11,269 shares. Utd Financial Advisers Limited Liability stated it has 0.02% of its portfolio in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT).

The stock decreased 0.40% or $0.02 during the last trading session, reaching $4.99. About 227,621 shares traded. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has risen 140.55% since December 22, 2016 and is uptrending. It has outperformed by 123.85% the S&P500.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: